Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07296523
Enrolling by invitation Observational

Expert Consensus on the Use of Isotretinoin in Acne Vulgaris: A Delphi Study

NCT07296523 · tracked via the Priya Life Science Egypt tracker
Sponsor
Venus Research Center
Phase
Observational
Started
2026-01-25
Last updated
2025-12-22

Condition(s) studied

IsotretinoinIsotretinoin Adverse ReactionAcne

Study summary

This study is a Delphi-based expert consensus project designed to establish evidence-informed, practical recommendations for the use of isotretinoin in acne vulgaris. Despite isotretinoin being the most effective therapy for severe and refractory acne, variations persist in its indications, dosing strategies, monitoring protocols, and safety counseling.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Board-certified or equivalent dermatologist, Minimum of 5 years of post-certification clinical experience in the management of acne vulgaris, Regular prescribing experience with oral isotretinoin in routine clinical practice, Willingness to participate in all Delphi rounds. Exclusion Criteria: * Inability or unwillingness to complete Delphi rounds.• Lack of clinical experience with isotretinoin.• Industry representatives without direct clinical practice

Primary outcome measure(s)

  • Primary Outcome — 6-12 weeks
    Level of expert consensus on key clinical statements regarding isotretinoin use in acne vulgaris, measured by the proportion of panelists achieving the predefined agreement threshold (e.g., ≥70-80% agreement) for each statement across Delphi rounds.

Trial sites (1)

FacilityCityRegionStatus
Venus Research Center Cairo Egypt

More Venus Research Center trials in Egypt

Expert Consensus on Photoprotection Practices: A Delphi Study Enrolling by invitation
Expert Consensus on the Use of Isotretinoin in Rejuvenation: A Delphi Study Enrolling by invitation
Consensus on Skin Care in Breast Cancer Patients Enrolling by invitation
Expert Consensus on the Use of Nutraceuticals in Pregnancy: A Delphi Study Enrolling by invitation
Consensus Guidelines for Pre- and Post-Procedure Skincare in Aesthetic Treatments Enrolling by invitation

Other trials for the same condition

Expert Consensus on the Use of Isotretinoin in Rejuvenation: A Delphi Study Enrolling by invitation
Assessment of the Efficacy of Topical Ketoconazole 2% Cream in Comparison With Topical Retinoids in the Treatment of Mild Comedonal and Papulopustular Acne Active, not recruiting
A Split-Face Comparative Study of Mono Threads Versus Combination With Plasma Gel for the Treatment of Post-Acne Scars Enrolling by invitation
Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris. Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07296523 on ClinicalTrials.gov ↗ ← All trials in Egypt